Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014

William Tillett, Lihi Eder, Niti Goel, Maarten De Wit, Dafna D Gladman, Oliver FitzGerald, Willemina Campbell, Philip S Helliwell, Laure Gossec, Ana-Maria Orbai, Alexis Ogdie, Vibeke Strand, Neil J McHugh, Philip J Mease

Research output: Contribution to journalArticle

  • 17 Citations

Abstract

OBJECTIVE: To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.

METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.

RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity."

CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.

LanguageEnglish
JournalThe Journal of Rheumatology
DOIs
StatusPublished - 1 May 2015

Fingerprint

Patient Participation
Psoriatic Arthritis
Psoriasis
Research
Outcome Assessment (Health Care)
Musculoskeletal Diseases
Spondylitis
Cytomegalovirus Infections
Rheumatology
Politics
Nails
Arthritis
Observational Studies
Fatigue
Longitudinal Studies
Randomized Controlled Trials
Skin

Cite this

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. / Tillett, William; Eder, Lihi; Goel, Niti; De Wit, Maarten; Gladman, Dafna D; FitzGerald, Oliver; Campbell, Willemina; Helliwell, Philip S; Gossec, Laure; Orbai, Ana-Maria; Ogdie, Alexis; Strand, Vibeke; McHugh, Neil J; Mease, Philip J.

In: The Journal of Rheumatology, 01.05.2015.

Research output: Contribution to journalArticle

Tillett, W, Eder, L, Goel, N, De Wit, M, Gladman, DD, FitzGerald, O, Campbell, W, Helliwell, PS, Gossec, L, Orbai, A-M, Ogdie, A, Strand, V, McHugh, NJ & Mease, PJ 2015, 'Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014' The Journal of Rheumatology. https://doi.org/10.3899/jrheum.141156
Tillett, William ; Eder, Lihi ; Goel, Niti ; De Wit, Maarten ; Gladman, Dafna D ; FitzGerald, Oliver ; Campbell, Willemina ; Helliwell, Philip S ; Gossec, Laure ; Orbai, Ana-Maria ; Ogdie, Alexis ; Strand, Vibeke ; McHugh, Neil J ; Mease, Philip J. / Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. In: The Journal of Rheumatology. 2015.
@article{94ad8174a4ba45a78641536f7e2fa3a4,
title = "Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014",
abstract = "OBJECTIVE: To discuss the need for revision of the {"}core set{"} of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100{\%}), and the inclusion of disease impact (94{\%}) and fatigue (72{\%}) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as {"}inflammatory musculoskeletal disease,{"} and nail and skin psoriasis as {"}psoriasis activity.{"}CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.",
author = "William Tillett and Lihi Eder and Niti Goel and {De Wit}, Maarten and Gladman, {Dafna D} and Oliver FitzGerald and Willemina Campbell and Helliwell, {Philip S} and Laure Gossec and Ana-Maria Orbai and Alexis Ogdie and Vibeke Strand and McHugh, {Neil J} and Mease, {Philip J}",
year = "2015",
month = "5",
day = "1",
doi = "10.3899/jrheum.141156",
language = "English",
journal = "The Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014

AU - Tillett, William

AU - Eder, Lihi

AU - Goel, Niti

AU - De Wit, Maarten

AU - Gladman, Dafna D

AU - FitzGerald, Oliver

AU - Campbell, Willemina

AU - Helliwell, Philip S

AU - Gossec, Laure

AU - Orbai, Ana-Maria

AU - Ogdie, Alexis

AU - Strand, Vibeke

AU - McHugh, Neil J

AU - Mease, Philip J

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVE: To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity."CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.

AB - OBJECTIVE: To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.METHODS: The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.RESULTS: Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity."CONCLUSION: Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.

UR - http://dx.doi.org/10.3899/jrheum.141156

U2 - 10.3899/jrheum.141156

DO - 10.3899/jrheum.141156

M3 - Article

JO - The Journal of Rheumatology

T2 - The Journal of Rheumatology

JF - The Journal of Rheumatology

SN - 0315-162X

ER -